Injectable GLP-1 drugs work better than the oral versions.
9 sources: 1 positive, 2 partly, 6 negative.
Researchers say
No researcher counted yet.
Studies show
1 positive, 2 partly, 6 negative
9 papers we read
-
Trial or observed group, J Endocrinol Invest, 2024, PMID 38683498
Positive Study
Read the paper on PubMed →After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
-
Systematic review, Front Endocrinol (Lausanne), 2023, PMID 37701904
Partly Study
Read the paper on PubMed →According to the SUCRA results, the ranking of HbA1c reduction from highest to lowest was as follows: tirzepatide15mg>semaglutide1.0mg>PEX168-200μg>dulaglutide1.5mg>oral semaglutide14mg>liraglutide1.8mg>albiglutide30mg>weekly-exenatide2.0mg>daily-exenatide10μg>lixisenatide20μg>placebo.
-
Systematic review, Diabetes Obes Metab, 2026, PMID 41992023
Partly Study
Read the paper on PubMed →Higher‐dose regimens (semaglutide 7.2 mg, orforglipron 36 mg and semaglutide 2.4 mg) demonstrated broader and more consistent improvements across cardiometabolic risk factors, whereas lower‐dose regimens showed more limited, domain‐specific effects.
-
Other primary study, Diabetes Ther, 2019, PMID 31599391
Negative Study
Read the paper on PubMed →Orally administered semaglutide 14 mg QD as an add-on to 1-2 OADs is one of the most efficacious GLP-1 RAs for reducing HbA1c and body weight at 26 ± 4 weeks.
-
Other primary study, Diabetes Ther, 2021, PMID 33723769
Negative Study
Read the paper on PubMed →Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs.
-
Other primary study, Cell Rep Med, 2021, PMID 34622228
Negative Study
Read the paper on PubMed →Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.
-
Other primary study, J Clin Med, 2024, PMID 39274378
Negative Study
Read the paper on PubMed →The oral formulation of semaglutide demonstrated equivalent effectiveness in glucose control and body weight management in patients with T2DM and CKD, even with a higher proportion of patients receiving low to medium doses.
-
Controlled trial, Diabetes Obes Metab, 2026, PMID 42225300
Negative Study
Read the paper on PubMed →This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.
-
Trial or observed group, Int J Mol Sci, 2026, PMID 42278227
Negative Study
Read the paper on PubMed →Oral and subcutaneous semaglutide show comparable effectiveness in lowering HbA1c and BMI in a real-world setting.
14 more not counted · see why
The study is not yet read in full. 12
- Controlled trial, JAMA, 2017, PMID 29049653
- Controlled trial, Lancet, 2019, PMID 31186120
- Controlled trial, Lancet Diabetes Endocrinol, 2020, PMID 32333875
- Controlled trial, Lancet Diabetes Endocrinol, 2020, PMID 32333876
- Systematic review, Diabetes Obes Metab, 2021, PMID 34047443
- Trial or observed group, Prim Care Diabetes, 2023, PMID 37230813
- Controlled trial, Lancet, 2023, PMID 37369232
- Trial or observed group, Diabetes Obes Metab, 2024, PMID 38477183
- Other primary study, J Pharm Technol, 2025, PMID 39545243
- Trial or observed group, Expert Rev Endocrinol Metab, 2025, PMID 39921267
- Pooled analysis, Pol Arch Intern Med, 2025, PMID 41117588
- Systematic review, Diabetes Obes Metab, 2026, PMID 41872986
A review or commentary, not a study. 2
Show the receipts from 9 sources
-
Trial or observed group, J Endocrinol Invest, 2024, PMID 38683498 Study · positive
After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
-
Systematic review, Front Endocrinol (Lausanne), 2023, PMID 37701904 Study · partly
According to the SUCRA results, the ranking of HbA1c reduction from highest to lowest was as follows: tirzepatide15mg>semaglutide1.0mg>PEX168-200μg>dulaglutide1.5mg>oral semaglutide14mg>liraglutide1.8mg>albiglutide30mg>weekly-exenatide2.0mg>daily-exenatide10μg>lixisenatide20μg>placebo.
-
Systematic review, Diabetes Obes Metab, 2026, PMID 41992023 Study · partly
Higher‐dose regimens (semaglutide 7.2 mg, orforglipron 36 mg and semaglutide 2.4 mg) demonstrated broader and more consistent improvements across cardiometabolic risk factors, whereas lower‐dose regimens showed more limited, domain‐specific effects.
-
Other primary study, Diabetes Ther, 2019, PMID 31599391 Study · negative
Orally administered semaglutide 14 mg QD as an add-on to 1-2 OADs is one of the most efficacious GLP-1 RAs for reducing HbA1c and body weight at 26 ± 4 weeks.
-
Other primary study, Diabetes Ther, 2021, PMID 33723769 Study · negative
Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs.
-
Other primary study, Cell Rep Med, 2021, PMID 34622228 Study · negative
Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.
-
Other primary study, J Clin Med, 2024, PMID 39274378 Study · negative
The oral formulation of semaglutide demonstrated equivalent effectiveness in glucose control and body weight management in patients with T2DM and CKD, even with a higher proportion of patients receiving low to medium doses.
-
Controlled trial, Diabetes Obes Metab, 2026, PMID 42225300 Study · negative
This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.
-
Trial or observed group, Int J Mol Sci, 2026, PMID 42278227 Study · negative
Oral and subcutaneous semaglutide show comparable effectiveness in lowering HbA1c and BMI in a real-world setting.